MX2017010625A - Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos. - Google Patents

Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos.

Info

Publication number
MX2017010625A
MX2017010625A MX2017010625A MX2017010625A MX2017010625A MX 2017010625 A MX2017010625 A MX 2017010625A MX 2017010625 A MX2017010625 A MX 2017010625A MX 2017010625 A MX2017010625 A MX 2017010625A MX 2017010625 A MX2017010625 A MX 2017010625A
Authority
MX
Mexico
Prior art keywords
microglobulin
kidneys
alpha
protection
radionuclide therapy
Prior art date
Application number
MX2017010625A
Other languages
English (en)
Inventor
Åkerström Bo
Erik Strand Sven-
Göran Gram Magnus
Thuy Tran Amanda
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of MX2017010625A publication Critical patent/MX2017010625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8114—Kunitz type inhibitors
    • G01N2333/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)

Abstract

Esta invención se refiere a a1-microglobulina (A1M) para uso en el diagnóstico o tratamiento de tumores malignos que requieren diagnóstico de radionúclidos (RD), terapia con radionucleidos (RNT) o radioinmunoterapia (RIT), respectivamente, en DONDE A1M se usa como un co-tratamiento a RD, RNT o RIT.
MX2017010625A 2015-02-25 2016-02-25 Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos. MX2017010625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570099 2015-02-25
PCT/EP2016/053904 WO2016135214A1 (en) 2015-02-25 2016-02-25 Alpha-1-microglobulin for use in the protection of kidneys in radionuclide therapy

Publications (1)

Publication Number Publication Date
MX2017010625A true MX2017010625A (es) 2017-11-15

Family

ID=52807486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010625A MX2017010625A (es) 2015-02-25 2016-02-25 Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos.

Country Status (13)

Country Link
US (1) US10960048B2 (es)
EP (1) EP3261680A1 (es)
JP (1) JP2016204360A (es)
KR (1) KR20170118924A (es)
CN (1) CN107257804A (es)
AU (1) AU2016223489A1 (es)
BR (1) BR112017017695A2 (es)
CA (1) CA2976697A1 (es)
EA (1) EA201791897A1 (es)
MX (1) MX2017010625A (es)
SG (1) SG11201706071RA (es)
TW (1) TW201643199A (es)
WO (1) WO2016135214A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501750A (ja) * 2017-11-03 2021-01-21 ガード セラピューティクス インターナショナル エービーＧｕａｒｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＡＢ 骨髄細胞の保護のためのアルファ−１−ミクログロブリンの使用
CN108440665B (zh) * 2018-03-27 2021-06-01 上海欣科医药有限公司 一种用于肺癌诊断的99mTC标记的生长抑素类似物及其制备方法
WO2024165674A1 (en) 2023-02-08 2024-08-15 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3819239B2 (ja) 1998-12-22 2006-09-06 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
EP1862172A1 (en) 2006-05-31 2007-12-05 BioSynthema Inc. Combination of amino acid solution and a gelatin for inhibiting renal uptake
BR112013031591A2 (pt) * 2011-06-07 2016-12-13 Caris Life Sciences Luxembourg Holdings S A R L biomarcadores de circulação para câncer
MX357656B (es) * 2012-09-05 2018-07-18 A1M Pharma Ab Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins

Also Published As

Publication number Publication date
CN107257804A (zh) 2017-10-17
EP3261680A1 (en) 2018-01-03
BR112017017695A2 (pt) 2018-04-10
WO2016135214A1 (en) 2016-09-01
TW201643199A (zh) 2016-12-16
EA201791897A1 (ru) 2018-01-31
AU2016223489A1 (en) 2017-09-14
CA2976697A1 (en) 2016-09-01
JP2016204360A (ja) 2016-12-08
US20180243369A1 (en) 2018-08-30
SG11201706071RA (en) 2017-09-28
US10960048B2 (en) 2021-03-30
KR20170118924A (ko) 2017-10-25

Similar Documents

Publication Publication Date Title
EP3153400B1 (en) MASK FOR USE UNDER WATER, IN PARTICULAR A FACIAL MASK
PH12015502075B1 (en) Treatment of cataplexy
EA201400178A1 (ru) Лечение рака молочной железы
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
DK3608425T3 (da) Hcbi, msbi, mssi og cmi sekvenser som en tidlig markør for den fremtidige udvikling af cancer og sygdomme i cns og som mål for behandling og forebyggelse af disse sygdom-me
SG10201804034QA (en) Methods for treating hypotension
PH12016502150A1 (en) Method for treating renal cell carcimona
PT3308781T (pt) Agente anti-hipertensor
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
MX2017010625A (es) Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2017007792A (es) Uso de ligandos del receptor sigma en la osteoartritis.
MY186523A (en) Macrocyclic rip2 kinase inhibitors
MX2018011379A (es) Tratamiento del prurito uremico.
MX2018003802A (es) Formulacion de hipericina para el diagnostico fotodinamico.
MX2017007676A (es) Nuevos compuestos.
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
MX2018003801A (es) Formulacion de hipericina para la terapia fotodinamica.
IN2014DE00883A (es)
EA201890230A1 (ru) Селективная к цезию смола
MX2017013669A (es) Composiciones para el tramiento del cancer.